225 related articles for article (PubMed ID: 30488179)
21. Do intravenous fluid substitutions influence methotrexate clearance? An unanticipated impact of an intravenous sodium bicarbonate drug shortage.
Mangum R; Bernhardt MB; Cheng WS; Schafer ES; Berg SL; Foster JH
Pediatr Blood Cancer; 2020 Sep; 67(9):e28334. PubMed ID: 32608575
[TBL] [Abstract][Full Text] [Related]
22. [Investigation on individualized adjustment of target range of high-dose methotrexate].
Hua Y; Zhao WH; Lu XT; Yang LH; Lu W
Zhonghua Er Ke Za Zhi; 2008 Mar; 46(3):203-8. PubMed ID: 19099710
[TBL] [Abstract][Full Text] [Related]
23. Case report on hypersensitivity to methotrexate infusion in a pediatric acute lymphoblastic leukaemia patient.
Sajith M; Pawar A; Bafna V; Bartakke S
J Oncol Pharm Pract; 2020 Mar; 26(2):462-464. PubMed ID: 30961436
[TBL] [Abstract][Full Text] [Related]
24. Population pharmacokinetics of high-dose methotrexate in children with acute lymphoblastic leukaemia.
Aumente D; Buelga DS; Lukas JC; Gomez P; Torres A; García MJ
Clin Pharmacokinet; 2006; 45(12):1227-38. PubMed ID: 17112298
[TBL] [Abstract][Full Text] [Related]
25. Shortening infusion time for high-dose methotrexate alters antileukemic effects: a randomized prospective clinical trial.
Mikkelsen TS; Sparreboom A; Cheng C; Zhou Y; Boyett JM; Raimondi SC; Panetta JC; Bowman WP; Sandlund JT; Pui CH; Relling MV; Evans WE
J Clin Oncol; 2011 May; 29(13):1771-8. PubMed ID: 21444869
[TBL] [Abstract][Full Text] [Related]
26. Solitary serum methotrexate level 36 hours post high-dose methotrexate: A safe, efficacious, and cost-effective strategy to monitor methotrexate toxicities in childhood leukemia in resource-limited centers.
Khera S; Kapoor R; Pramanik SK
Pediatr Blood Cancer; 2020 Jul; 67(7):e28387. PubMed ID: 32400952
[TBL] [Abstract][Full Text] [Related]
27. Monitoring Of High-Dose Methotrexate (Mtx)-Related Toxicity and Mtx Levels in Children with Acute Lymphoblastic Leukemia: A Pilot-Study in Indonesia.
Sari NM; Rakhmilla LE; Bashari MH; Zazuli Z; Suryawan N; Susanah S; Reniarti L; Raspati H; Supriyadi E; Kaspers GJL; Idjradinata P
Asian Pac J Cancer Prev; 2021 Jul; 22(7):2025-2031. PubMed ID: 34319023
[TBL] [Abstract][Full Text] [Related]
28. Dosing algorithm to target a predefined AUC in patients with primary central nervous system lymphoma receiving high dose methotrexate.
Joerger M; Ferreri AJ; Krähenbühl S; Schellens JH; Cerny T; Zucca E; Huitema AD
Br J Clin Pharmacol; 2012 Feb; 73(2):240-7. PubMed ID: 21838788
[TBL] [Abstract][Full Text] [Related]
29. Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate.
Masson E; Relling MV; Synold TW; Liu Q; Schuetz JD; Sandlund JT; Pui CH; Evans WE
J Clin Invest; 1996 Jan; 97(1):73-80. PubMed ID: 8550853
[TBL] [Abstract][Full Text] [Related]
30. Population Pharmacokinetic Study and Individual Dose Adjustments of High-Dose Methotrexate in Chinese Pediatric Patients With Acute Lymphoblastic Leukemia or Osteosarcoma.
Hui KH; Chu HM; Fong PS; Cheng WTF; Lam TN
J Clin Pharmacol; 2019 Apr; 59(4):566-577. PubMed ID: 30556906
[TBL] [Abstract][Full Text] [Related]
31. Evaluating Intestinal Permeability by Measuring Plasma Endotoxin and Diamine Oxidase in Children with Acute Lymphoblastic Leukemia Treated with High-dose Methotrexate.
Meng Y; Zhang Y; Liu M; Huang YK; Zhang J; Yao Q; Zhao YL; Xiong JJ
Anticancer Agents Med Chem; 2016; 16(3):387-92. PubMed ID: 26265099
[TBL] [Abstract][Full Text] [Related]
32. The impact of high-dose methotrexate on intracellular 6-mercaptopurine disposition during interval therapy of childhood acute lymphoblastic leukemia.
Adam de Beaumais T; Dervieux T; Fakhoury M; Medard Y; Azougagh S; Zhang D; Yakouben K; Jacqz-Aigrain E
Cancer Chemother Pharmacol; 2010 Sep; 66(4):653-8. PubMed ID: 20033410
[TBL] [Abstract][Full Text] [Related]
33. Preventing and Managing Toxicities of High-Dose Methotrexate.
Howard SC; McCormick J; Pui CH; Buddington RK; Harvey RD
Oncologist; 2016 Dec; 21(12):1471-1482. PubMed ID: 27496039
[TBL] [Abstract][Full Text] [Related]
34. Delayed methotrexate clearance in patients with acute lymphoblastic leukemia concurrently receiving dasatinib.
Ramsey LB; Mizuno T; Vinks AA; O'Brien MM
Pediatr Blood Cancer; 2019 May; 66(5):e27618. PubMed ID: 30677213
[TBL] [Abstract][Full Text] [Related]
35. High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma.
Jahnke K; Korfel A; Martus P; Weller M; Herrlinger U; Schmittel A; Fischer L; Thiel E;
Ann Oncol; 2005 Mar; 16(3):445-9. PubMed ID: 15653703
[TBL] [Abstract][Full Text] [Related]
36. Population pharmacokinetic analysis of high-dose methotrexate in pediatric and adult oncology patients.
Kawakatsu S; Nikanjam M; Lin M; Le S; Saunders I; Kuo DJ; Capparelli EV
Cancer Chemother Pharmacol; 2019 Dec; 84(6):1339-1348. PubMed ID: 31586225
[TBL] [Abstract][Full Text] [Related]
37. Renal dysfunction during and after high-dose methotrexate.
Green MR; Chamberlain MC
Cancer Chemother Pharmacol; 2009 Mar; 63(4):599-604. PubMed ID: 18504579
[TBL] [Abstract][Full Text] [Related]
38. Resumption of high-dose methotrexate after acute kidney injury and glucarpidase use in pediatric oncology patients.
Christensen AM; Pauley JL; Molinelli AR; Panetta JC; Ward DA; Stewart CF; Hoffman JM; Howard SC; Pui CH; Pappo AS; Relling MV; Crews KR
Cancer; 2012 Sep; 118(17):4321-30. PubMed ID: 22252903
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetic basis for dosing high-dose methotrexate in infants and young children with malignant brain tumours.
Panetta JC; Roberts JK; Huang J; Lin T; Daryani VM; Harstead KE; Patel YT; Onar-Thomas A; Campagne O; Ward DA; Broniscer A; Robinson G; Gajjar A; Stewart CF
Br J Clin Pharmacol; 2020 Feb; 86(2):362-371. PubMed ID: 31657864
[TBL] [Abstract][Full Text] [Related]
40. Clinical covariates that improve the description of high dose methotrexate pharmacokinetics in a diverse population to inform MTXPK.org.
Taylor ZL; Miller TP; Poweleit EA; DeGroote NP; Pommert L; Awoniyi O; Board SG; Ugboh N; Joshi V; Ambrosino N; Chavana A; Bernhardt MB; Schafer ES; O'Brien MM; Castellino SM; Ramsey LB
Clin Transl Sci; 2023 Nov; 16(11):2130-2143. PubMed ID: 37503924
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
